Type 1 Diabetes Mellitus Associated with Nivolumab after Second SARS-CoV-2 Vaccination, Japan

Recently, along with increasing use of immune checkpoint inhibitors such as nivolumab, the incidence of immune-related adverse events, including type 1 diabetes mellitus, has become a serious problem. We report a patient who had immune checkpoint inhibitor‒associated type 1 diabetes mellitus that de...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato, Toshihiro, Kodama, Shinjiro, Kaneko, Keizo, Imai, Junta, Katagiri, Hideki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239866/
https://www.ncbi.nlm.nih.gov/pubmed/35468049
http://dx.doi.org/10.3201/eid2807.220127
_version_ 1784737405675241472
author Sato, Toshihiro
Kodama, Shinjiro
Kaneko, Keizo
Imai, Junta
Katagiri, Hideki
author_facet Sato, Toshihiro
Kodama, Shinjiro
Kaneko, Keizo
Imai, Junta
Katagiri, Hideki
author_sort Sato, Toshihiro
collection PubMed
description Recently, along with increasing use of immune checkpoint inhibitors such as nivolumab, the incidence of immune-related adverse events, including type 1 diabetes mellitus, has become a serious problem. We report a patient who had immune checkpoint inhibitor‒associated type 1 diabetes mellitus that developed after a second mRNA-based SARS-CoV-2 vaccination.
format Online
Article
Text
id pubmed-9239866
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-92398662022-07-06 Type 1 Diabetes Mellitus Associated with Nivolumab after Second SARS-CoV-2 Vaccination, Japan Sato, Toshihiro Kodama, Shinjiro Kaneko, Keizo Imai, Junta Katagiri, Hideki Emerg Infect Dis Research Letter Recently, along with increasing use of immune checkpoint inhibitors such as nivolumab, the incidence of immune-related adverse events, including type 1 diabetes mellitus, has become a serious problem. We report a patient who had immune checkpoint inhibitor‒associated type 1 diabetes mellitus that developed after a second mRNA-based SARS-CoV-2 vaccination. Centers for Disease Control and Prevention 2022-07 /pmc/articles/PMC9239866/ /pubmed/35468049 http://dx.doi.org/10.3201/eid2807.220127 Text en https://creativecommons.org/licenses/by/4.0/Emerging Infectious Diseases is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Research Letter
Sato, Toshihiro
Kodama, Shinjiro
Kaneko, Keizo
Imai, Junta
Katagiri, Hideki
Type 1 Diabetes Mellitus Associated with Nivolumab after Second SARS-CoV-2 Vaccination, Japan
title Type 1 Diabetes Mellitus Associated with Nivolumab after Second SARS-CoV-2 Vaccination, Japan
title_full Type 1 Diabetes Mellitus Associated with Nivolumab after Second SARS-CoV-2 Vaccination, Japan
title_fullStr Type 1 Diabetes Mellitus Associated with Nivolumab after Second SARS-CoV-2 Vaccination, Japan
title_full_unstemmed Type 1 Diabetes Mellitus Associated with Nivolumab after Second SARS-CoV-2 Vaccination, Japan
title_short Type 1 Diabetes Mellitus Associated with Nivolumab after Second SARS-CoV-2 Vaccination, Japan
title_sort type 1 diabetes mellitus associated with nivolumab after second sars-cov-2 vaccination, japan
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239866/
https://www.ncbi.nlm.nih.gov/pubmed/35468049
http://dx.doi.org/10.3201/eid2807.220127
work_keys_str_mv AT satotoshihiro type1diabetesmellitusassociatedwithnivolumabaftersecondsarscov2vaccinationjapan
AT kodamashinjiro type1diabetesmellitusassociatedwithnivolumabaftersecondsarscov2vaccinationjapan
AT kanekokeizo type1diabetesmellitusassociatedwithnivolumabaftersecondsarscov2vaccinationjapan
AT imaijunta type1diabetesmellitusassociatedwithnivolumabaftersecondsarscov2vaccinationjapan
AT katagirihideki type1diabetesmellitusassociatedwithnivolumabaftersecondsarscov2vaccinationjapan

Ejemplares similares